Equities research analysts forecast that RVL Pharmaceuticals plc (NASDAQ:RVLP – Get Rating) will announce sales of $15.11 million for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for RVL Pharmaceuticals’ earnings, with the highest sales estimate coming in at $24.54 million and the lowest estimate coming in at $8.50 million. RVL Pharmaceuticals reported sales of $11.51 million during the same quarter last year, which would indicate a positive year over year growth rate of 31.3%. The business is scheduled to issue its next quarterly earnings results on Monday, January 1st.
On average, analysts expect that RVL Pharmaceuticals will report full-year sales of $58.20 million for the current fiscal year, with estimates ranging from $45.10 million to $73.61 million. For the next financial year, analysts anticipate that the firm will post sales of $119.20 million, with estimates ranging from $102.30 million to $131.13 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that cover RVL Pharmaceuticals.
RVL Pharmaceuticals (NASDAQ:RVLP – Get Rating) last posted its quarterly earnings data on Wednesday, March 30th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.03). RVL Pharmaceuticals had a negative net margin of 160.51% and a negative return on equity of 92.86%. During the same period in the prior year, the business earned ($0.26) earnings per share.
NASDAQ:RVLP opened at $1.45 on Friday. The company has a market cap of $121.15 million, a price-to-earnings ratio of -1.65 and a beta of 1.78. RVL Pharmaceuticals has a 1 year low of $0.98 and a 1 year high of $4.85. The company has a 50 day moving average of $1.64. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.95 and a quick ratio of 2.91.
RVL Pharmaceuticals Company Profile (Get Rating)
RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. The company is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults.
- Get a free copy of the StockNews.com research report on RVL Pharmaceuticals (RVLP)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for RVL Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RVL Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.